Patents by Inventor David T. Jonaitis
David T. Jonaitis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11827600Abstract: This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.Type: GrantFiled: July 12, 2022Date of Patent: November 28, 2023Assignee: Acadia Pharmaceuticals Inc.Inventors: Matthew Peterson, Marlon Carlos, Martin Bernard Catherine Bousmanne, Cecilia Betti, David T. Jonaitis, Lisa M. McCracken, Lisa M. Grove
-
Publication number: 20230023114Abstract: This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.Type: ApplicationFiled: July 12, 2022Publication date: January 26, 2023Inventors: Matthew PETERSON, Marlon CARLOS, Martin Bernard Catherine BOUSMANNE, Cecilia BETTI, David T. JONAITIS, Lisa M. MCCRACKEN, Lisa M. GROVE
-
Publication number: 20220409572Abstract: The invention relates to a solid ?9-THC composition containing ?9-THC and a powder former and having a molar ratio of ?9-THC to powder former to form a flowable ?9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?9-THC composition of the invention. The ?9-THC may be synthetic ?9-THC or may be extracted ?9-THC.Type: ApplicationFiled: August 25, 2022Publication date: December 29, 2022Applicant: CANNA CHEMISTRIES LLCInventors: Emily RIGSBEE, David T. JONAITIS, Nathan SCHULTHEISS, Lloyd Steven MILLER
-
Patent number: 11478447Abstract: The invention relates to a solid ?9-THC composition containing ?9-THC and a powder former and having a molar ratio of ?9-THC to powder former to form a flowable ?9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?9-THC composition of the invention. The ?9-THC may be synthetic ?9-THC or may be extracted ?9-THC.Type: GrantFiled: January 13, 2022Date of Patent: October 25, 2022Assignee: CANNA CHEMISTRIES LLCInventors: Emily Rigsbee, David T. Jonaitis, Nathan Schultheiss, Lloyd Steven Miller
-
Patent number: 11324769Abstract: The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.Type: GrantFiled: July 28, 2020Date of Patent: May 10, 2022Assignee: Astrocyte Pharmaceuticals, Inc.Inventors: Russell Birch Poe, David T. Jonaitis, Lisa Michelle Grove
-
Publication number: 20220133686Abstract: The invention relates to a solid ?9-THC composition containing ?9-THC and a powder former and having a molar ratio of ?9-THC to powder former to form a flowable ?9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?9-THC composition of the invention. The ?9-THC may be synthetic ?9-THC or may be extracted ?9-THC.Type: ApplicationFiled: January 13, 2022Publication date: May 5, 2022Inventors: Emily RIGSBEE, David T. JONAITIS, Nathan SCHULTHEISS, Lloyd Steven MILLER
-
Publication number: 20220117912Abstract: A cocrystal of cannabidiol is disclosed, specifically a 1:1 cannabidiokL-pipecolic acid cocrystal The beneficial and therapeutic uses of the cocrystal and of compositions containing the cocrystal are also disclosed. The disclosure sets out methods of making and characterizing the cocrystal.Type: ApplicationFiled: February 14, 2020Publication date: April 21, 2022Inventors: David T. JONAITIS, Nathan SCHULTHEISS
-
Publication number: 20220016072Abstract: The invention relates to a solid ?9-THC composition containing ?9-THC and a powder former and having a molar ratio of ?9-THC to powder former to form a flowable ?9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?9-THC composition of the invention. The ?9-THC may be synthetic ?9-THC or may be extracted ?9-THC.Type: ApplicationFiled: July 16, 2021Publication date: January 20, 2022Inventors: Emily RIGSBEE, David T. JONAITIS, Nathan SCHULTHEISS
-
Publication number: 20210315909Abstract: The present invention provides co-crystal and salt forms, and compositions and methods thereof, useful for treating various diseases, disorders or conditions in which EP4 prostaglandin receptors are implicated in the mediation of a proliferative disorder, by the administration of small molecule therapeutics acting as inhibitors of prostaglandin EP4 receptor activity.Type: ApplicationFiled: July 11, 2019Publication date: October 14, 2021Inventors: Alfredo C. CASTRO, David T. JONAITIS
-
Publication number: 20210077518Abstract: The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.Type: ApplicationFiled: July 28, 2020Publication date: March 18, 2021Inventors: Russell Birch POE, David T. JONAITIS, Lisa Michelle GROVE
-
Patent number: 10765693Abstract: The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.Type: GrantFiled: September 26, 2019Date of Patent: September 8, 2020Assignee: Astrocyte Pharmaceuticals, Inc.Inventors: Russell Birch Poe, David T. Jonaitis, Lisa Michelle Grove
-
Publication number: 20200093848Abstract: The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.Type: ApplicationFiled: September 26, 2019Publication date: March 26, 2020Inventors: Russell Birch Poe, David T. Jonaitis, Lisa Michelle Grove
-
Patent number: 8633243Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.Type: GrantFiled: June 29, 2012Date of Patent: January 21, 2014Assignee: Reata Pharmaceuticals, Inc.Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, Jr.
-
Patent number: 8592600Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.Type: GrantFiled: November 4, 2010Date of Patent: November 26, 2013Assignee: Il Yang Pharmaceutical Company, Ltd.Inventors: John M. Brackett, David T. Jonaitis, Wei Lai, Jih Hua Liu, Stephan D. Parent, Jinyu Shen
-
Patent number: 8592599Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl)1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.Type: GrantFiled: November 4, 2010Date of Patent: November 26, 2013Assignee: Il Yang Pharmaceutical Company, Ltd.Inventors: John M. Brackett, David T. Jonaitis, Wei Lai, Jih Hua Liu, Stephan D. Parent, Jinyu Shen
-
Publication number: 20120330050Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.Type: ApplicationFiled: June 29, 2012Publication date: December 27, 2012Inventors: John WALLING, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, JR.
-
Patent number: 8309601Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.Type: GrantFiled: November 29, 2011Date of Patent: November 13, 2012Assignee: Reata Pharmaceuticals, Inc.Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, Jr.
-
Publication number: 20120071684Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.Type: ApplicationFiled: November 29, 2011Publication date: March 22, 2012Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, JR.
-
Patent number: 8088824Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.Type: GrantFiled: August 13, 2008Date of Patent: January 3, 2012Assignee: Reata Pharmaceuticals Inc.Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, Jr.
-
Patent number: 7999110Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2 -pyridinyl)-methyl]sulfinyl]-5-(1 H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.Type: GrantFiled: December 28, 2007Date of Patent: August 16, 2011Assignee: IL Yang Pharmaceutical Company, Ltd.Inventors: John M. Brackett, David T. Jonaitis, Wei Lai, Jih Hua Liu, Stephan D. Parent, Jinyu Shen